SC
LOGC

Samlyn Capital’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Samlyn Capital’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,511,417
Closed -$3.49M – 152
2021
Q4 		$3.49M Buy
1,511,417
+37,309
+3% +$126K 0.05% 109
2021
Q3 		$6.75M Buy
1,474,108
+53,656
+4% +$236K 0.09% 107
2021
Q2 		$6.31M Buy
1,420,452
+20,608
+1% +$105K 0.09% 91
2021
Q1 		$10.2M Sell
1,399,844
-17,602
-1% -$145K 0.14% 91
2020
Q4 		$10.8M Buy
1,417,446
+643,551
+83% +$4.31M 0.15% 92
2020
Q3 		$7.03M Sell
773,895
-13,120
-2% -$99.5K 0.13% 92
2020
Q2 		$6.66M Sell
787,015
-11,551
-1% -$76K 0.12% 92
2020
Q1 		$3.94M Buy
798,566
+58,520
+8% +$455K 0.1% 72
2019
Q4 		$5.33M Buy
740,046
+100,069
+16% +$904K 0.11% 85
2019
Q3 		$6.92M Buy
639,977
+1,478
+0.2% +$15.8K 0.17% 84
2019
Q2 		$8.3M Buy
638,499
+4,216
+0.7% +$56K 0.18% 97
2019
Q1 		$6.27M Buy
634,283
+84,744
+15% +$789K 0.15% 92
2018
Q4 		$5.72M Buy
+549,539
New +$6.64M 0.14% 97

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Samlyn Capital's LOGC Position: Q1 2022 in Review

Samlyn Capital sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q1 2022, closing a stake of 1,511,417 shares — an estimated $3.49M sold.

Samlyn Capital first reported a position in LOGC in Q4 2018 and held it in 13 quarters. The position peaked at $10.8M in Q4 2020. 46 funds tracked by Wall St. Rank hold LOGC as of Q1 2022.

  • Samlyn Capital reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Samlyn Capital sold 1,511,417 LogicBio Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $3.49M.
  • Samlyn Capital first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2018 and held it in 13 quarters.
  • Samlyn Capital's LogicBio Therapeutics, Inc. Common Stock position peaked at $10.8M in Q4 2020.
  • 46 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Samlyn Capital's 13F filing for Q1 2022, filed 16 May 2022.